{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:10:19Z","timestamp":1792026619844,"version":"4.4.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62176230"],"award-info":[{"award-number":["62176230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Medical and Health Science and Technology Project","award":["2022KY827"],"award-info":[{"award-number":["2022KY827"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs), known for their potent acid-suppressing effects, are widely used in various clinical settings, including treatment and prevention. Understanding their adverse effects is crucial. This study, utilizing the FDA Adverse Event Reporting System (FAERS) database, comprehensively analyzes PPI-related adverse events to guide clinical medication practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed suspected adverse drug reactions (ADRs) related to specific PPI drugs using data from the FAERS database, covering Q1 2004 to Q4 2024. Multiple statistical methods, including ROR, PRR, IC025, and EBGM, were employed for evaluation, with ADRs defined according to System Organ Class (SOC) and Preferred Term (PT). A comparative analysis was conducted to assess potential differences in ADR profiles among different PPI drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study analyzed 176,680 cases of PPI-related adverse events, with a total of 632,468 adverse reaction reports recorded when PPIs were designated as the primary suspected drug (PS). PPIs showed significantly elevated risks in the renal\/urinary and gastrointestinal systems, with other common adverse reactions including hypomagnesemia, hypocalcemia, and renal anemia. Most adverse reactions occurred either within the first 0\u201330 days of use or after prolonged exposure (&gt;6 months), and elderly patients (\u226565 years) were disproportionately affected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For high-risk populations using PPIs long-term (such as elderly patients or those with pre-existing renal impairment), continuous monitoring is essential to mitigate potential complications. Unnecessary use should be strictly avoided, and long-term medication should be minimized to ensure safety and appropriateness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340684","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:46:04Z","timestamp":1770057964000},"page":"e0340684","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database"],"prefix":"10.1371","volume":"21","author":[{"given":"Zhenyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8014-529X","authenticated-orcid":true,"given":"Jianan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"4","key":"pone.0340684.ref001","article-title":"The mortality risk of proton pump inhibitors in 1.9 million us seniors: an extended cox survival analysis","volume":"20","author":"SH Baik","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0340684.ref002","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s12325-017-0532-9","article-title":"A review of the novel application and potential adverse effects of proton pump inhibitors","volume":"34","author":"L-Y Yu","year":"2017","journal-title":"Adv Ther"},{"issue":"18","key":"pone.0340684.ref003","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents","volume":"118","author":"DL Bhatt","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"pone.0340684.ref004","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/0366-6999.173480","article-title":"Study of clinical and genetic risk factors for aspirin-induced gastric mucosal injury","volume":"129","author":"Y Wu","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"pone.0340684.ref005","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"P Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"pone.0340684.ref006","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.amjmed.2016.03.042","article-title":"Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial","volume":"129","author":"M Vaduganathan","year":"2016","journal-title":"Am J Med"},{"issue":"1","key":"pone.0340684.ref007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13054-016-1305-6","article-title":"Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials","volume":"20","author":"F Alshamsi","year":"2016","journal-title":"Crit Care"},{"issue":"25","key":"pone.0340684.ref008","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H , K )-ATPase by proton pump inhibitors","volume":"126","author":"JM Shin","year":"2004","journal-title":"J Am Chem Soc"},{"issue":"2","key":"pone.0340684.ref009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"PF Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"pone.0340684.ref010","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2008.01975.x","article-title":"Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients","volume":"103","author":"M Aseeri","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"pone.0340684.ref011","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/j.gastro.2010.08.023","article-title":"Safety of proton pump inhibitor exposure","volume":"139","author":"Y-X Yang","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0340684.ref012","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jgh.15151","article-title":"Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data","volume":"36","author":"G Chen","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0340684.ref013","doi-asserted-by":"crossref","first-page":"767987","DOI":"10.3389\/fcvm.2022.767987","article-title":"Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study","volume":"9","author":"Y Zhai","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"pone.0340684.ref014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jgh.16411","article-title":"A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database","volume":"39","author":"Y Sun","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0340684.ref015","doi-asserted-by":"crossref","first-page":"1524903","DOI":"10.3389\/fphar.2024.1524903","article-title":"A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database","volume":"15","author":"Y-J Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0340684.ref016","doi-asserted-by":"crossref","first-page":"1515847","DOI":"10.3389\/fmed.2024.1515847","article-title":"A study on the pharmacovigilance of various SGLT-2 inhibitors","volume":"11","author":"Y Dong","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"pone.0340684.ref017","doi-asserted-by":"crossref","first-page":"31201","DOI":"10.1038\/s41598-024-82575-5","article-title":"Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database","volume":"14","author":"H Pan","year":"2024","journal-title":"Sci Rep"},{"key":"pone.0340684.ref018","article-title":"Esomeprazole: a review of its use in the management of acid-related disorders","author":"LJ Scott","year":"2000","journal-title":"Drugs"},{"key":"pone.0340684.ref019","first-page":"1","article-title":"Safety assessment of esomeprazole: real-world adverse event signal mining and analysis based on FAERS database","author":"B Wang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"pone.0340684.ref020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pds.4963","article-title":"Overuse of proton pump inhibitors in nursing homes: An Italian multicenter observational study","volume":"29","author":"L Pasina","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"pone.0340684.ref021","first-page":"738","article-title":"The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China","volume":"111","author":"J Ying","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"pone.0340684.ref022","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","article-title":"Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury","volume":"91","author":"Y Xie","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"pone.0340684.ref023","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0002-9343(92)90181-A","article-title":"Acute interstitial nephritis due to omeprazole","volume":"93","author":"SJ Ruffenach","year":"1992","journal-title":"Am J Med"},{"issue":"8836","key":"pone.0340684.ref024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0140-6736(93)92531-W","article-title":"Renal failure after omeprazole","volume":"341","author":"PB Christensen","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"pone.0340684.ref025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"B Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"8","key":"pone.0340684.ref026","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","article-title":"Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)","volume":"22","author":"D Jain","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0340684.ref027","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1038\/s41598-021-83099-y","article-title":"Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system","volume":"11","author":"B Wu","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0340684.ref028","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","article-title":"Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium","volume":"12","author":"T Ito","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"issue":"24","key":"pone.0340684.ref029","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Y-X Yang","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"pone.0340684.ref030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"P Vestergaard","year":"2006","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"pone.0340684.ref031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/qjmed\/hcq021","article-title":"Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series","volume":"103","author":"JD Mackay","year":"2010","journal-title":"QJM"},{"issue":"2","key":"pone.0340684.ref032","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MOG.0b013e32833ff5d6","article-title":"Proton pump inhibitors and severe hypomagnesaemia","volume":"27","author":"T Cundy","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"issue":"13","key":"pone.0340684.ref033","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015011","article-title":"Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis","volume":"98","author":"S Liao","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"pone.0340684.ref034","article-title":"Mechanisms of proton pump inhibitor-induced hypomagnesemia","volume":"235","author":"LMM Gommers","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"issue":"4","key":"pone.0340684.ref035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2012.452","article-title":"Proton-pump inhibitor use is associated with low serum magnesium concentrations","volume":"83","author":"J Danziger","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0340684.ref036","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1253\/circj.CJ-14-0582","article-title":"Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients","volume":"79","author":"T Shikata","year":"2015","journal-title":"Circ J"},{"issue":"3","key":"pone.0340684.ref037","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jamda.2007.10.004","article-title":"Do acid-lowering agents affect vitamin B12 status in older adults?","volume":"9","author":"TS Dharmarajan","year":"2008","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"pone.0340684.ref038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mcna.2018.08.002","article-title":"Proton pump inhibitor-refractory gastroesophageal reflux disease","volume":"103","author":"R Yadlapati","year":"2019","journal-title":"Med Clin North Am"},{"issue":"10","key":"pone.0340684.ref039","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.3390\/ijms25105459","article-title":"Rebound acid hypersecretion after withdrawal of long-term proton pump inhibitor (PPI) treatment-are PPIs addictive?","volume":"25","author":"K Namikawa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"pone.0340684.ref040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.ajkd.2019.07.012","article-title":"Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe","volume":"75","author":"Z Al-Aly","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"pone.0340684.ref041","article-title":"Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Y Xie","year":"2017","journal-title":"BMJ Open"},{"issue":"9","key":"pone.0340684.ref042","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/00912709922008542","article-title":"Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure","volume":"39","author":"WF Keane","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"pone.0340684.ref043","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinternmed.2011.89","article-title":"The FDA drug safety surveillance program: adverse event reporting trends","volume":"171","author":"S Weiss-Smith","year":"2011","journal-title":"Arch Intern Med"},{"key":"pone.0340684.ref044","doi-asserted-by":"crossref","DOI":"10.4103\/0976-500X.120955","article-title":"Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two \u201cchallenging\u201d case reports","volume":"4","author":"C Palleria","year":"2013","journal-title":"J Pharmacol Pharmacother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:46:11Z","timestamp":1770057971000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340684"}},"subtitle":[],"editor":[{"given":"Sara","family":"Mucherino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340684","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}